Yeungnam Univ J Med.  2020 Oct;37(4):329-331. 10.12701/yujm.2020.00108.

Negative myoclonus associated with tramadol use

• Bae SY
• Lee SJ

• KMID: 2508179
• DOI: http://doi.org/10.12701/yujm.2020.00108

Abstract

Negative myoclonus (NM) is a shock-like jerky involuntary movement caused by a sudden, brief interruption of tonic muscle contraction. NM is observed in patients diagnosed with epilepsy, metabolic encephalopathy, and drug toxicity and in patients with brain lesions. A 55-year-old man presented with NM in both his arms and neck. He has taken medications containing tramadol at a dose of 80–140 mg/day for 5 days due to common cold. He had no history of seizures. Acute lesions were not observed during magnetic resonance imaging, and abnormal findings in his laboratory tests were not noted. His NM resolved completely after the discontinuation of tramadol and the oral administration of clonazepam. Our case report suggests that tramadol can cause NM in patients without seizure history or metabolic disorders, even within its therapeutic dose.

Keyword

Negative myoclonus; Negative myoclonus; Seizure; Seizure; Tramadol; Tramadol

Reference

References

1. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol Clin. 2006; 36:337–43.

2. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011; 4:47–62.

3. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci. 2017; 7:103.

4. Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY. Negative myoclonus induced by gabapentin and pregabalin: a case series and systematic literature review. J Neurol Sci. 2017; 382:36–9.

5. Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin. 2006; 36:333–6.

6. Jovanovic-Cupic V, Martinovic Z, Nesic N. Seizures associated with intoxication and abuse of tramadol. Clin Toxicol (Phila). 2006; 44:143–6.

7. Talaie H, Panahandeh R, Fayaznouri M, Asadi Z, Abdollahi M. Dose-independent occurrence of seizure with tramadol. J Med Toxicol. 2009; 5:63–7.

8. Boostani R, Derakhshan S. Tramadol induced seizure: a 3-year study. Caspian J Intern Med. 2012; 3:484–7.

9. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43:879–923.

10. Rehni AK, Singh I, Kumar M. Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. Basic Clin Pharmacol Toxicol. 2008; 103:262–6.

11. Pappert EJ, Goetz CG, Stebbins GT, Belden M, Carvey PM. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol. 1998; 347:51–6.

12. Pranzatelli MR. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol. 1994; 51:605–17.

13. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000; 41:479–81.

14. Park KD, Kim MK, Lee SJ. Negative myoclonus associated with pregabalin. Yeungnam Univ J Med. 2018; 35:240–3.

15. Li JY, Cunic DI, Paradiso G, Gunraj C, Pal PK, Lang AE, et al. Electrophysiological features of myoclonus-dystonia. Mov Disord. 2008; 23:2055–61.